Eli Lilly slashes insulin prices by 70%, places $35 monthly out-of-pocket cap

dml5050/iStock via Getty Images

• Eli Lilly (NYSE:LLY) is cutting the prices of its insulin drugs by 70% and introducing a program that will cap out-of-pocket expenses at $35 per month.
• The reductions impact Insulin Lispro, Humalog (insulin lispro injection), and Humulin (insulin human).
• The drug giant is also launchign Rezvoglar (insulin glargine-aglr), a basal insulin that is biosimilar to Sanofi's (SNY) Lantus (insulin glargine) injection, for $92 per five pack, a 78% discount to Lantus, beginning April 1.
• The $35 cap applies to individuals with commercial insurance at retail pharmacies.
• Those without insurance can get get Lilly (LLY) insulins under the $35 cap through the Lilly Insulin Value Program.
• In August 2022, a the Inflation Reduction Act passed the Senate with a provision on capping monthly insulin out-of-pockets costs for commercial insurance stripped.

Comments

[Tiger80]

The government forced Eli Lilly's hand in this and I believe due to Lilly's decision most Americans will end up getting their insulin made in China or India as a generic drug which is dangerous. Yes Lilly will cut the price but eventually you will see it will become a generic coming from India and elsewhere.

[miriam64]

Always liked pharmaceuticals. When a company as this slices their prices they will be lauded, other companies will follow and do the same.. the share prices will do up and diabetics will not have to Sacrifice so much! Miriam64

[Martin Keck]

@miriam64 why will profit and share price go up, when you lower prices?

[Izet]

All it took was the California State government to start manufacturing it's own insulin for other manufactures to cut prices. Good work California.

[Investor since ‘73]

Proud to be a long term holder of LLY, it’s been a great investment and the best is yet to come. This is a great move, a welcome relief for millions of Americans and their diabetes/obesity drug will be the holy grail, making Viagra look like a little niche drug. Then there’s the Alzheimer’s drug that worked so well they had to stop the trial to expand it because so many subjects responded so quickly they stopped taking it before the end date. A new, larger study will unleash the dam and the profits will flow like a river.

LLY and MP are my two highest confidence picks for the year. And years to come.

[Tiger80]

@Investor since ‘73 Lilly makes money but usually after it makes the dough, it has to give up the drug that made them rich. Remember Darvocet-N , Bextra, and than Zyprexa the anti psychotic and bi-polar drug that made everyone gain so much weight they became diabetic. Yes Lilly, made money, but in terms of decency, average rating

[bill h illify]

You are welcome.

[Memeearl]

@bill h illify you’re

[DW2340]

Good for them and good for all those who struggle to pay for such a necessary drug

[Stefan Redlich]

Good move